Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Background: This study aimed to investigate the clinical utility of different soluble suppression of tumorigenicity 2 (sST2) levels in assessing the severity and prognosis of patients with acute heart failure (AHF).
Methods: This was a prospective cohort study. Three hundred and thirty-one consecutively enrolled AHF patients from March 2018 to November 2019 were divided into 3 subgroups according to sST2 levels: T1 (1.15-7.70 ng/ml; = 110), T2 (7.71-17.24 ng/ml; = 111), and T3 (17.26-47.42 ng/ml; = 110). The patients were followed up for a median period of 21.0 months for the development of the primary endpoint. Cox proportional hazards model was performed to evaluate the prognostic value of sST2 for the clinical outcomes.
Results: The mean age of patients was 69 years (range, 34-93 years), and 70.4% were male. During the follow-up period, 63 participants died. Patients with higher sST2 levels had lower left ventricular ejection fraction (correlation = -0.119, = 0.031), and higher New York Heart Association classification (correlation = 0.443, < 0.001) and N-terminal pro-B type natriuretic peptide (NT-proBNP) levels (correlation = 0.392, < 0.001). Higher sST2 was also associated with creatinine, urea nitrogen, hemoglobin, and left ventricular mass index. Multivariate analysis revealed that sST2 (per log unit, hazard ratio: 2.174, 95% confidence interval [CI] 1.012-4.67, = 0.047) and NT-proBNP (per log unit, HR 2.171, 95%CI 1.169-4.032, < 0.001) were independent risk factors for the primary outcome in all patients with AHF.
Conclusion: sST2 can provide prognostic information in AHF. The higher the sST2 level in patients with AHF, the higher the incidence of cardiovascular death.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8863653 | PMC |
| http://dx.doi.org/10.3389/fcvm.2022.812654 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
MR-proANP, sST2, BNP and sinus rhythm maintenance 1 year after electrical cardioversion for atrial fibrillation.
BMC Cardiovasc Disord
August 2025
Department of Cardiology, University Hospital Besançon, Boulevard Fleming, 25000, Besançon, France.
Background: We assessed the ability of MR-proANP, sST2 and BNP to predict maintenance of sinus rhythm at one year after successful electrical cardioversion of atrial fibrillation.
Methods: Prospective, multicenter, observational study including patients undergoing electrical cardioversion of persistent AF. MR-proANP, sST2 and BNP were measured in peripheral venous blood before cardioversion.
Dynamics of the Novel Cardiac Biomarkers sST2, H-FABP, GDF-15 and suPAR in HFrEF Patients Undergoing Heart Failure Therapy, a Pilot Study.
J Clin Med
August 2025
Department of Internal Medicine II, Paracelsus Medical University, 5020 Salzburg, Austria.
Despite improvements in medical therapy, heart failure with reduced ejection fraction (HFrEF) is a major burden on the healthcare system and remains a leading cause of death with a 5-year mortality rate of more than 60%. Novel therapeutic agents such as angiotensin-receptor-neprilysin-inhibitors (ARNIs) lead to significant improvement in clinical outcomes. Optimal therapy monitoring under these novel drugs is crucial for improving the outcome.
View Article and Find Full Text PDFLow Levels of Adropin Predicted New Incidents of Atrial Fibrillation in Patients with Heart Failure with Preserved Ejection Fraction.
Biomolecules
August 2025
Department of Internal Medicine II, Division of Cardiology, Paracelsus Medical University, 5020 Salzburg, Austria.
Background: Atrial fibrillation (AF) is common complication of heart failure with preserved ejection fraction (HFpEF) that sufficiently intervenes in the prognosis. The aim of the study is a) to investigate the possible discriminative value of adropin for newly onset AF in patients with HFpEF without a previous history of AF and who are being treated in accordance with conventional guideline and b) to compare it with predictive potencies of conventionally used predictors.
Methods: A total of 953 patients with HFpEF who had sinus rhythm on ECG were enrolled in the study.
Study of independent diagnostic efficacy and co-diagnostic strategies of molecular markers for diabetic cardiomyopathy.
Front Endocrinol (Lausanne)
August 2025
Department of Endocrinology, Second Affiliated Hospital of Shandong First Medical University, Tai'an, China.
Word count of the full article: 4834Diabetic cardiomyopathy (DCM) is defined as myocardial dysfunction in diabetes mellitus (DM) patients independent of coronary artery disease (CAD) or hypertension (HTN). With high morbidity and mortality, DCM poses a significant threat to patient health. Its underlying pathogenesis remains incompletely elucidated, and the prolonged subclinical phase renders early diagnosis and precise treatment clinically challenging.
View Article and Find Full Text PDFThe clinical value of serum sST2 and cfDNA in guiding evidence-based nursing care for children with severe pneumonia complicated by myocardial damage.
J Med Biochem
July 2025
Capital Medical University, Baoding Hospital of Beijing Children's Hospital, Pediatrics, China.
Background: To investigate how serum sST2 and cfDNA can be used to inform evidence-based nursing practices for children with severe pneumonia and myocardial damage.
Methods: 100 children with severe pneumonia complicated with myocardial damage were recruited as research subjects. After assessing serum sST2 and cfDNA concentrations, the individuals were categorised into a control cohort (receiving standard treatment, n=50) and an experimental cohort (receiving evidence-based treatment guided by serum sST2 and cfDNA markers, n=50).